Radiopharmaceuticals in nasopharyngeal Cancer

Bioorganic Chemistry, Год журнала: 2025, Номер 157, С. 108281 - 108281

Опубликована: Фев. 14, 2025

Язык: Английский

---

Development of Antibody–Drug Conjugates for Malignancies of the Uterine Corpus: A Review

Cells, Год журнала: 2025, Номер 14(5), С. 333 - 333

Опубликована: Фев. 24, 2025

Despite recent advances in cancer treatment, the prognosis for uterine malignancies (carcinoma and sarcoma) requires further improvement. Antibody-drug conjugates (ADCs) have emerged as a novel class of anti-cancer therapeutic agents, multiple ADCs been approved other types cancer. In 2024, trastuzumab deruxtecan received approval from US Food Drug Administration became first ADC treatment malignancies. Many are currently being investigated malignancies, therefore, there is need to gain deeper understanding ADCs. this article, we aim provide comprehensive overview advancements The contents article include structure mechanism action, an analysis clinical trials, expected future questions. This also focuses on sarcoma, which not often highlighted target treatment.

Язык: Английский

---

Summary and Future Directions of Antibody-Drug Conjugates

AAPS advances in the pharmaceutical sciences series, Год журнала: 2025, Номер unknown, С. 275 - 296

Опубликована: Янв. 1, 2025

Язык: Английский

---

Complementing Anticancer Therapy: Antibody-Drug Conjugates Targeting CD46 as Prostate Cancer Treatment

Journal of Clinical Oncology, Год журнала: 2025, Номер unknown

Опубликована: Апрель 22, 2025

Язык: Английский

---

Platinum Resistance in Ovarian Cancer: Is This the End of the Line?

EMJ Oncology, Год журнала: 2024, Номер unknown, С. 69 - 79

Опубликована: Окт. 29, 2024

Approximately 80% of females with ovarian cancer are diagnosed advanced disease, and around 70% these relapse within 3 years first-line treatment. Five-year survival for newly is less than 50%. Platinum-based chemotherapy the cornerstone systemic treatment; however, it not appropriate patients relapsed who had disease progression during previous platinum treatment, early symptomatic post-platinum or intolerant. New drugs needed to address unmet need in eligible platinum-based chemotherapy. This article presents highlights from a satellite symposium conducted as part European Society Medical Oncology (ESMO) Congress 2024, which took place 13th–17th September 2024 Barcelona, Spain. The objectives were improve understanding current treatment pathways needs ineligible therapies, raise awareness rationale targeting folate receptor α (FRα) variety novel therapeutics platinum-resistant (PROC), review efficacy outcomes side effects recent clinical trials involving antibody–drug conjugates (ADC) PROC. In this symposium, Ana Oaknin, Vall d’Hebron University Hospital, Spain, described landscape disease; Philipp Harter, Evangelische Kliniken Essen-Mitte, Germany, explored FRα-targeted PROC; Kathleen Moore, Stephenson Cancer Center, Oklahoma, Norman, USA, discussed ADC development beyond FRα concluded lively discussion, including questions audience, key examples included article.

Язык: Английский

---

The interaction of isoquinoline alkaloid crebanine with immunoglobulin G and cytotoxic effects toward MCF-7 breast cancer cell line

International Journal of Biological Macromolecules, Год журнала: 2024, Номер unknown, С. 139194 - 139194

Опубликована: Дек. 1, 2024

Язык: Английский

---